Piper Sandler analyst Matt O’Brien reiterated an Overweight rating and $106 price target on Integer (ITGR). Boston Scientific (BSX) received a PMA supplement for its SCS Systems where Integer is approved as an alternate supplier for the Proximal Contact and Distal Electrode components used in Boston’s Neuromodulation Spinal Cord Stimulator and Deep Brain Stimulation Leads and Lead Products, which Piper Sandler anticipates will be a “nice” tailwind Integer’s business in 2024 and beyond.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ITGR:
- Integer to Showcase Latest Innovations in Neuromodulation Miniaturization During NANS 2024 Annual Meeting
- Integer price target raised to $100 from $86 at Wells Fargo
- Integer Holdings Corporation Announces Preliminary Unaudited Sales Results and Acquisition of Pulse Technologies
- Integer to Participate in 42nd Annual J.P. Morgan Healthcare Conference
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
